Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 4 1

Status

Unknown 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 20Carcinoma, Hepatocellular 8Stomach Neoplasms 6Multiple Myeloma 6Colorectal Neoplasms 6Uterine Cervical Neoplasms 4Endometrial Neoplasms 4Small Cell Lung Carcinoma 3Recurrence 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Melanoma 3Febrile Neutropenia 3Waldenstrom Macroglobulinemia 2Venous Thromboembolism 2Skin Neoplasms 2Pancreatic Neoplasms 2Pancreatic Cancer Non-resectable 2Obesity 2Neoplasm Metastasis 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hepatitis B 2Hematologic Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms 2Anemia 2

Interventions

naxitamab 1Isotretinoin 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Not yet recruiting × Neuroblastoma × Clear all
NCT06047535 2023-09-21

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

SciClone Pharmaceuticals

Phase 4 Not yet recruiting
62 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡